Therapeutic Nanoparticle Synthesis Using Stable Mucic Acid Intermediates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for synthesizing nanoparticles containing chemotherapeutics like camptothecin and its derivatives are reagent- and time-intensive, require elevated temperatures, and provide low yields, making them inefficient for delivering therapeutic molecules across the blood-brain and blood-tumor barriers.
Innovation Solution
Improved methods for synthesizing mucic acid-polyethylene glycol (PEG) polymer-based nanoparticles using more stable reactants and intermediates, with rapid reaction times and higher yields, incorporating chemotherapeutics such as camptothecin and its derivatives, and novel linkers for conjugating targeting molecules.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If existing methods for synthesizing nanoparticles containing camptothecin and its derivatives are used, then the nanoparticles can be formed, but the methods are reagent- and time-intensive, require elevated temperatures, and provide low yields
Solution Approach 1:
The patent changes the chemical parameters of the synthesis method by using activated mucic acid monomer with specific functional groups and optimizing reaction conditions (temperature, pH, reagent ratios) to achieve higher yields and faster reaction times while maintaining nanoparticle stability and therapeutic efficacy
Solution Approach 2:
The patent introduces activated mucic acid monomer as a key intermediary that facilitates efficient polymerization and subsequent conjugation of camptothecin derivatives, enabling the synthesis to proceed with higher yield and reduced reaction time compared to conventional methods
2Productivity
If existing synthesis methods are used, then nanoparticles can be formed, but the methods are reagent- and time-intensive
Solution Approach 1:
The patent optimizes reagent parameters by using activated mucic acid monomer with specific functional groups and controlling reaction conditions (temperature, pH, reagent ratios) to minimize reagent consumption while maximizing nanoparticle yield and maintaining therapeutic efficacy
3Productivity
If existing synthesis methods are used, then nanoparticles can be formed, but they require elevated temperatures
Solution Approach 1:
The patent changes the temperature parameter by using activated mucic acid monomer that enables polymerization and conjugation at lower temperatures, reducing energy consumption while maintaining high yield and nanoparticle stability through optimized reaction conditions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The improved methods result in more stable intermediates, faster reaction times, and higher yields of therapeutic nanoparticles, enhancing their ability to cross biological barriers and deliver chemotherapeutics effectively.
Implementation Method 1
conversion of the therapeutic molecule to a selectively reactive derivative, and (4) attachment of one or more of the derivatized therapeutic molecules to the MAP
Implementation Method 2
the homing molecule binds to the transferrin receptor present on the surface of brain endothelial cells (and endothelial cells of tumor vasculature), which allows the nanoparticle to cross the endothelial cell by transcytosis
Implementation Method 3
camptothecin, an alkaloid that inhibits DNA topoisomerase I, thereby preventing cell division
Data Source
AI summary
Improved methods and reactants for the chemical synthesis of therapeutic nanoparticles are provided. The nanoparticles comprise a polymeric core, to which is attached one or more homing molecules and one or more therapeutic agents. Improvements in speed, yield and purity are attained using the methods disclosed herein.